Cicoira M, Davos C H, Florea V, Shamim W, Doehner W, Coats A J, Anker S D
Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom.
Am Heart J. 2001 Jul;142(1):174-80. doi: 10.1067/mhj.2001.115796.
Chronic heart failure (CHF) is a frequent disease with a dismal prognosis, but little is known about survival in the very elderly. There are no data on the prognostic value of cardiopulmonary exercise testing in this population. We aimed to assess exercise capacity, survival, and prognostic parameters in elderly patients with CHF.
We evaluated 188 patients with CHF >70 years old (mean 77 +/- 4 years, range 70-94 years) seen at our heart failure clinic between March 1992 and June 1998. A cardiopulmonary exercise test was performed in 102 patients (peak VO2 15.3 +/- 4.7, VE/VCO2 slope 39.6 +/- 15.01). All patients were followed up for at least 12 months. The prognostic end point of the study was all-cause mortality.
At the end of follow-up (16 +/- 10 mo, range 12-41 mo), 67 patients (35.6%) had died (1-year mortality rate 26% [95% confidence interval 20-32]). In univariate analysis New York Heart Association class (NYHA) (relative risk [RR] = 2.56, P <.0001), VE/VCO2 (RR = 1.041, P <.0001), peak VO2 (RR = 0.87, P =.0007), and fractional shortening (RR = 0.95, P <.0001) predicted mortality. Peak VO2 predicted mortality independently of age, NYHA class, and left ventricular ejection fraction. A subgroup of 12 patients with dynamic left ventricular outflow tract obstruction during stress had an excellent outcome, with a 100% survival at the end of follow-up (mean 16 +/- 7 mo, range 12-39 mo).
The prognosis in elderly patients with CHF is poor. Valid exercise testing results can be obtained in more than 50% of elderly patients with CHF. NYHA class and peak VO2 are the strongest prognostic factors in this population.
慢性心力衰竭(CHF)是一种常见疾病,预后不佳,但对于高龄患者的生存情况了解甚少。目前尚无关于该人群心肺运动试验预后价值的数据。我们旨在评估老年CHF患者的运动能力、生存率及预后参数。
我们对1992年3月至1998年6月期间在我们心力衰竭门诊就诊的188例年龄>70岁的CHF患者(平均77±4岁,范围70 - 94岁)进行了评估。对102例患者进行了心肺运动试验(峰值VO₂ 15.3±4.7,VE/VCO₂斜率39.6±15.01)。所有患者均随访至少12个月。该研究的预后终点为全因死亡率。
随访结束时(16±10个月,范围12 - 41个月),67例患者(35.6%)死亡(1年死亡率26% [95%置信区间20 - 32])。单因素分析显示,纽约心脏协会分级(NYHA)(相对风险[RR]=2.56,P<.0001)、VE/VCO₂(RR = 1.041,P<.0001)、峰值VO₂(RR = 0.87,P =.0007)和缩短分数(RR = 0.95,P<.0001)可预测死亡率。峰值VO₂独立于年龄、NYHA分级和左心室射血分数预测死亡率。12例在应激时出现动态左心室流出道梗阻的患者亚组预后良好,随访结束时生存率为100%(平均16±7个月,范围12 - 39个月)。
老年CHF患者预后较差。超过50%的老年CHF患者可获得有效的运动试验结果。NYHA分级和峰值VO₂是该人群最强的预后因素。